Spain has become the latest European country to launch a comprehensive pharmaceutical sector reform, seeking to slice off €2.4 billion ($3.4 billion) from its annual drugs budget as part of a desperate attempt to boost its flagging economy.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
